Description
BSE announces listing and trading of 18,19,21,827 equity shares of Viyash Scientific Ltd issued pursuant to composite scheme of amalgamation, effective January 29, 2026.
Summary
BSE has approved the listing and trading of 18,19,21,827 equity shares (face value Rs. 2/- each) of Viyash Scientific Ltd (Scrip Code: 512529, formerly known as Sequent Scientific Ltd). These shares are issued pursuant to a composite scheme of amalgamation involving Sequent Scientific Limited and nine other companies including Symed Labs Limited, Vandana Life Sciences Private Limited, Appcure Labs Private Limited, Vindhya Pharma (India) Private Limited, S.V. Labs Private Limited, Vindhya Organics Private Limited, Viyash Life Sciences Private Limited, Geninn Life Sciences Private Limited, and Sequent Research Limited. The new shares rank pari-passu with existing equity shares.
Key Points
- 18,19,21,827 new equity shares of Rs. 2/- face value to be listed
- Scrip Code: 512529
- ISIN Number: INE807F01027
- Company name changed from Sequent Scientific Ltd to Viyash Scientific Ltd
- Shares issued under composite scheme of amalgamation involving 10 companies
- New shares rank pari-passu with existing equity shares
- Allotment completed on December 16, 2025
- Distinctive Numbers: 254112650 to 436034476
Regulatory Changes
No new regulatory changes introduced. This listing follows the composite scheme of amalgamation approved under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013.
Compliance Requirements
- Market participants must note the listing of new securities for trading purposes
- The expanded share capital must be reflected in trading systems and records
- For clarifications, contact BSE at 022-2272 5271 / 5878
Important Dates
- Allotment Date: December 16, 2025
- Notice Date: January 28, 2026
- Trading Commencement Date: January 29, 2026 (Thursday)
Impact Assessment
The listing of approximately 18.19 crore new equity shares represents a substantial increase in the share capital of Viyash Scientific Ltd following the amalgamation of nine entities. This merger consolidates operations across multiple pharmaceutical and life sciences companies. The dilution impact will depend on the pre-existing share capital, but the large number of new shares may affect liquidity and trading patterns. Shareholders of the transferor companies now hold equity in the amalgamated entity. The name change from Sequent Scientific to Viyash Scientific reflects the post-merger identity. Market participants should adjust their records and systems to account for the increased float and monitor trading volumes on the commencement date.
Impact Justification
Significant listing of new equity shares following complex merger involving multiple entities. Material impact on shareholders and trading volumes but routine corporate action.